These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15211169)

  • 21. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
    Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M
    Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elderly heart failure patients with drug-induced serious hyperkalemia.
    Vanpee D; Swine CH
    Aging (Milano); 2000 Aug; 12(4):315-9. PubMed ID: 11073352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Life-threatening hyperkalemia: a potentially lethal drug combination.
    Juvet T; Gourineni VC; Ravi S; Zarich SW
    Conn Med; 2013 Sep; 77(8):491-3. PubMed ID: 24156179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness and impact of 10 gram glucose and 10 units insulin in treating hyperkalemia during living donor liver transplantation.
    Yang SC; Wang CH; Chen CL; Cheng KW; Wu SC; Shih TH; Jawan B; Huang CJ
    Acta Chir Belg; 2014; 114(6):400-3. PubMed ID: 26021685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug safety in patients with heart failure.
    Juurlink DN; Hansten PD
    Arch Intern Med; 2005 Jan; 165(1):118. PubMed ID: 15642888
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
    Bounthavong M; Butler J; Dolan CM; Dunn JD; Fisher KA; Oestreicher N; Pitt B; Hauptman PJ; Veenstra DL
    Pharmacoeconomics; 2018 Dec; 36(12):1463-1473. PubMed ID: 30194623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Spironolactone and potassium].
    Kjeldsen K
    Ugeskr Laeger; 2004 Nov; 166(48):4392; author reply 4392-3. PubMed ID: 15587639
    [No Abstract]   [Full Text] [Related]  

  • 28. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    BMJ; 2003 Nov; 327(7424):1141-2. PubMed ID: 14615339
    [No Abstract]   [Full Text] [Related]  

  • 30. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
    Wrenger E; Müller R; Moesenthin M; Welte T; Frölich JC; Neumann KH
    BMJ; 2003 Jul; 327(7407):147-9. PubMed ID: 12869459
    [No Abstract]   [Full Text] [Related]  

  • 32. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R; Grancelli HO; Miriuka SG
    Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Letter: Management of hyperkalemia during necessary spironolactone administration].
    Lohmann FW
    Dtsch Med Wochenschr; 1976 Jun; 101(25):975. PubMed ID: 1278018
    [No Abstract]   [Full Text] [Related]  

  • 34. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urea and spironolactone therapy].
    Schwarzbach W; Bunzl W
    Munch Med Wochenschr; 1973 Jan; 115(3):76-80. PubMed ID: 4739290
    [No Abstract]   [Full Text] [Related]  

  • 36. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart failure drug poses potassium problems. When using "the water pill" spironolactone, watch your potassium intake and check your levels.
    Harv Heart Lett; 2004 Dec; 15(4):3. PubMed ID: 15704264
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictive Risk Factors in the Development of Intraoperative Hyperkalemia in Adult Living Donor Liver Transplantation.
    Juang SE; Huang CE; Chen CL; Wang CH; Huang CJ; Cheng KW; Wu SC; Shih TH; Yang SC; Wong ZW; Jawan B; Lee YE
    Transplant Proc; 2016 May; 48(4):1022-4. PubMed ID: 27320547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spironolactone and congestive heart-failure.
    Georges B; Beguin C; Jadoul M
    Lancet; 2000 Apr; 355(9212):1369-70. PubMed ID: 10776778
    [No Abstract]   [Full Text] [Related]  

  • 40. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.